NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Panacea Biotec Secures INR 20.79 Crore Vaccine Supply Order from CMSS
Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for the supply of Diphtheria and Tetanus (Td) vaccines. The total value of the contract is INR 20.79 Crore. The supply is scheduled to be executed in multiple tranches starting from September/October 2026 and concluding by November/December 2028. This domestic order provides long-term revenue visibility for the company's vaccine segment.
முக்கிய அம்சங்கள்
Total contract value aggregates to INR 20.79 Crore for Td Vaccine supplyOrder awarded by Central Medical Services Society (CMSS), a domestic government entityExecution timeline spans approximately two years from late 2026 to late 2028The contract involves Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP
👀 கவனிக்க வேண்டியவை
Investors should note this as a positive development for revenue stability, though the execution starts in late 2026. Monitor the company's ability to secure similar high-volume government contracts to improve its order book.
Emmbi Industries Short-Term Credit Rating Upgraded to CARE A2
CARE Ratings has upgraded Emmbi Industries' short-term bank facility rating from CARE A3+ to CARE A2, indicating improved liquidity and creditworthiness for short-term obligations. The long-term bank facility rating has been reaffirmed at CARE BBB+ with a Stable outlook. This rating action reflects the company's ability to maintain its financial profile while enhancing its short-term debt servicing capabilities. The upgrade is a positive signal regarding the company's operational efficiency and working capital management.
முக்கிய அம்சங்கள்
Short-term bank facility rating upgraded from CARE A3+ to CARE A2Long-term bank facility rating reaffirmed at CARE BBB+ with a Stable outlookThe upgrade applies to combined Long Term / Short Term Bank FacilitiesRating action conducted by CARE Ratings Limited as of April 10, 2026
👀 கவனிக்க வேண்டியவை
Investors should take this upgrade as a positive sign of improving financial health and liquidity. Monitor the company's interest coverage ratio in upcoming earnings to see if the upgrade leads to lower borrowing costs.
Binani Industries has responded to NSE's clarification request regarding its Q2 FY25 financial results, citing auditor errors for subsidiary count discrepancies and technical faults for filing delays. The company's financial position is extremely weak, with accumulated losses of ₹21,682 lakhs and a fully eroded net worth. Liabilities exceed total assets by ₹18,543 lakhs, leading auditors to conclude that the 'going concern' assumption is no longer valid. Consequently, the financial statements have been prepared on a liquidation basis, reflecting severe financial distress.
முக்கிய அம்சங்கள்
Accumulated losses reached ₹21,682 lakhs with liabilities exceeding assets by ₹18,543 lakhs as of September 30, 2024.Auditors stated the 'going concern' assumption is inappropriate and financials are prepared on a liquidation basis.Outstanding corporate guarantees and letters of comfort total approximately ₹13,196 lakhs for erstwhile subsidiaries.Reported a standalone net loss of ₹54 lakhs for Q2 FY25 on zero operating income.Clarified that one subsidiary was struck off in FY 2023-24, leading to previous reporting errors by auditors.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company's net worth is fully eroded and it is being valued on a liquidation basis. The significant contingent liabilities and lack of a clear business plan suggest a very high risk of capital loss.
IFB Industries Appoints Sandeep Joseph Abraham as MD & CEO for 5-Year Term
IFB Industries has appointed Mr. Sandeep Joseph Abraham as its new Managing Director and Chief Executive Officer for a five-year term effective April 9, 2026. Mr. Abraham is a seasoned leader with over 30 years of experience, including a significant 11-year tenure as Vice President at MRF and an MBA from IIM Ahmedabad. The company also strengthened its board by appointing Mr. Manoj Kumar Vijay, who has 36 years of experience in finance and legal matters, as an Independent Director for two years. These leadership changes are aimed at driving growth and operational excellence across IFB's diverse business segments.
முக்கிய அம்சங்கள்
Mr. Sandeep Joseph Abraham appointed as MD & CEO for a 5-year tenure starting April 9, 2026New CEO brings 30+ years of experience and previously managed business operations worth nearly ₹20,000 croreMr. Manoj Kumar Vijay appointed as Independent Director for a 2-year term to enhance board governanceAppointments are subject to shareholder approval via General Meeting or Postal BallotMr. Abraham's professional background includes leadership roles at MRF, GSK Consumer Healthcare, and Vodafone
👀 கவனிக்க வேண்டியவை
Investors should view this leadership transition positively given Mr. Abraham's extensive experience in scaling large businesses. Monitor upcoming quarterly calls for the new CEO's strategic roadmap for the company's consumer and industrial segments.
Biocon Receives US FDA Approval for Dapagliflozin Tablets (5 mg and 10 mg)
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received US FDA approval for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The drug is indicated for glycemic control in adults with type 2 diabetes and for reducing heart failure hospitalization risks. This approval strengthens Biocon's integrated diabetes portfolio, which includes oral solids, biosimilar insulin, and GLP-1 peptides. The product will be manufactured at Biocon's existing FDA-approved facilities, ensuring high-quality production standards for the US market.
முக்கிய அம்சங்கள்
Received US FDA approval for Dapagliflozin Tablets in 5 mg and 10 mg dosages.Indicated for type 2 diabetes treatment and reduction of heart failure hospitalization risk.Expands Biocon's global diabetes portfolio across oral solids and biosimilars.Manufacturing to be handled at the company's own FDA-approved facilities.Strengthens the company's position in the high-value US pharmaceutical market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive milestone that enhances Biocon's revenue potential in the US generic market. Monitor the commercial launch timeline and the company's ability to capture market share in the SGLT2 inhibitor segment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
A B Infrabuild Secures ₹42.68 Crore Railway Contract for Road Over Bridge Construction
A B Infrabuild Limited has received a Letter of Acceptance from East Coast Railways for the construction of a Road Over Bridge (ROB) between Baruva and Mandasa stations. The contract is valued at approximately ₹42.68 Crore, representing a significant addition to the company's order book. The project involves various engineering components including composite and T-beam girders. The execution period for this domestic contract is set at 24 months, providing revenue visibility for the next two fiscal years.
முக்கிய அம்சங்கள்
Total contract value stands at ₹42,68,20,821.94 awarded by East Coast Railways.Project involves construction of a Road Over Bridge (ROB) at Railway Km 662/9-11.The execution timeline for the entire project is 24 months.The contract is a domestic order with no promoter or related party interest involved.
👀 கவனிக்க வேண்டியவை
Investors should track the company's execution progress over the 24-month period and monitor for any further order wins from Indian Railways which could signal a strengthening market position.
IFB Industries Appoints Mr. Arup Das as Executive Director Effective April 2026
IFB Industries has appointed Mr. Arup Das as an Additional Director in the category of Executive Director, effective April 1, 2026. Mr. Das is a company veteran with over 34 years of experience at IFB and a total professional background of 38 years. This appointment is for an interim period until a permanent Chief Executive Officer or Managing Director is appointed. His deep internal knowledge across engineering, marketing, and M&A divisions is expected to provide leadership stability during this transition.
முக்கிய அம்சங்கள்
Appointment of Mr. Arup Das as Executive Director for an interim period starting April 2026.Mr. Das has been with IFB Industries since 1992, totaling 34 years of internal experience.He possesses over 38 years of total experience in marketing, sales, and general management.The role is temporary until the company identifies and appoints a new permanent CEO or Managing Director.Mr. Das currently serves as the President of M&A and New Projects for the company.
👀 கவனிக்க வேண்டியவை
Investors should view this as a move to ensure operational continuity while the company searches for a permanent top executive. Monitor future announcements regarding the permanent CEO/MD appointment for long-term strategic clarity.
Concord Biotech Acquires 100% Stake in Celliimune Biotech for Rs 66 Lakhs
Concord Biotech has completed the 100% acquisition of Celliimune Biotech Private Limited for a cash consideration of Rs 66 lakhs. Celliimune is a biopharmaceutical startup focused on pioneering DNA engineering for cancer therapeutics and cell/gene therapy solutions. While the target entity currently has nil turnover, the acquisition is a strategic move to enter the high-growth oncology research space. This transaction is classified as a related party transaction as the promoter group previously held a majority stake in the target entity.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in Celliimune Biotech Private Limited for Rs 66,00,000Target entity focuses on DNA engineering for cancer therapeutics and cell/gene therapy solutionsCelliimune was incorporated in January 2025 and currently reports nil turnoverTransaction is a related party deal as promoters previously held majority controlAcquisition completed on April 02, 2026, via cash consideration
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term R&D play rather than an immediate revenue driver. Monitor for future updates on clinical breakthroughs or product development from this new subsidiary.
Birla Cable Credit Rating Revised; CE Facilities Downgraded to CARE A (CE) Amid Merger Watch
CARE Ratings has downgraded Birla Cable's credit-enhanced bank facilities totaling ₹296 crore following a downgrade of its guarantor, Vindhya Telelinks Limited (VTL). The downgrade is attributed to VTL's moderate operations, execution delays in its EPC segment, and a stretched operating cycle with debtors rising to ₹2,191.85 crore. However, BCL's standalone rating of ₹55 crore is on 'Positive Watch' due to its proposed merger into VTL, which is expected to streamline operations over the next 10-12 months. BCL's own performance showed revenue growth to ₹557 crore in 9MFY26, though margins slightly compressed to 4.66%.
முக்கிய அம்சங்கள்
Downgraded ₹120 Cr long-term and ₹176 Cr short-term CE facilities to CARE A (CE) and CARE A1 (CE) respectively.Guarantor Vindhya Telelinks saw debtors increase from ₹1,527.71 Cr in FY25 to ₹2,191.85 Cr as of December 2025.BCL standalone rating (₹55 Cr) placed on 'Rating Watch with Positive Implications' due to the VTL merger.Merger swap ratio confirmed at 10 equity shares of VTL for every 115 shares of BCL held.BCL 9MFY26 revenue rose to ₹557 Cr from ₹505 Cr YoY, but operating margins dipped to 4.66% from 4.93%.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the merger progress with Vindhya Telelinks and the liquidity position of the guarantor, as the downgrade reflects execution challenges in the EPC segment. The positive watch on the standalone rating suggests potential long-term benefits from the amalgamation despite current credit-enhancement downgrades.
SBI Card Appoints Amit Batra as EVP & Chief Strategy Officer Effective July 2026
SBI Cards and Payment Services has announced the appointment of Mr. Amit Batra as Executive Vice President & Chief Strategy Officer, effective July 01, 2026. Mr. Batra brings approximately 30 years of leadership experience in strategy, operations, and business transformation. He joins from TransUnion CIBIL India, where he served as Chief Operating Officer, and has prior experience with GE Capital and a previous stint at SBI Card. This appointment is aimed at strengthening the company's strategic planning and operational resilience.
முக்கிய அம்சங்கள்
Mr. Amit Batra appointed as EVP & Chief Strategy Officer with effect from July 01, 2026Possesses approximately 30 years of experience in leadership roles across strategy, ESG, and operationsPreviously served as Chief Operating Officer at TransUnion CIBIL India leading enterprise transformationAlumnus of INSEAD and a Master Black Belt in Lean Six Sigma with past experience at GE Capital and SBI Card
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive leadership reinforcement given Mr. Batra's deep background in credit bureau operations and strategy. No immediate action is required as the appointment is effective from July 2026.
Tasty Bite Appoints Rahul Bhatnagar as Chairman Effective April 1, 2026
Tasty Bite Eatables Limited has appointed Mr. Rahul Bhatnagar as the Chairman and Non-Executive Independent Director, effective April 1, 2026. Mr. Bhatnagar is a seasoned executive with over 40 years of experience in FMCG and telecom, having held senior roles at Bharti Enterprises, PepsiCo, and Seagram. He previously managed a portfolio generating $1.2 billion in revenue as Managing Director and CFO at Bharti Enterprises. This appointment brings high-caliber leadership and deep industry expertise to the board.
முக்கிய அம்சங்கள்
Mr. Rahul Bhatnagar appointed as Chairman and Non-Executive Independent Director effective April 1, 2026Brings over 40 years of experience across FMCG, telecommunications, and consulting sectorsPreviously served as MD and CFO at Bharti Enterprises, managing a $1.2 billion revenue portfolioEducational background includes being a Chartered Accountant and an MBA from Wharton
👀 கவனிக்க வேண்டியவை
Investors should view this leadership transition positively due to Mr. Bhatnagar's extensive FMCG experience. No immediate action is required, but monitor for potential strategic shifts under his guidance.
Ambika Cotton Mills Promoters Declare Zero Encumbrance on 50.35% Stake
Promoters of Ambika Cotton Mills Limited have officially declared that there are no encumbrances or pledges on their shareholding as of April 2026. The promoter group, consisting of Sri P.V. Chandran and Smt. C. Bhavani, collectively holds 2,882,350 shares, representing 50.35% of the company's total equity. Specifically, Sri P.V. Chandran holds 10.65% while Smt. C. Bhavani holds 39.70%. This disclosure, filed under SEBI SAST Regulations, confirms that the promoters have not used their equity as collateral for loans.
முக்கிய அம்சங்கள்
Promoters confirm zero encumbrance on their entire 50.35% equity stakeSri P.V. Chandran holds 6,09,784 shares (10.65% of total equity)Smt. C. Bhavani holds 22,72,566 shares (39.70% of total equity)Total promoter group holding stands at 28,82,350 shares out of 57,25,000 total shares
👀 கவனிக்க வேண்டியவை
The absence of pledged shares is a positive indicator of promoter financial health and reduces the risk of forced selling. Investors can maintain their positions as this reinforces the company's stable ownership structure.
SBI Life Shareholders Approve Material Related Party Transactions with Over 97% Majority
SBI Life Insurance has successfully obtained shareholder approval for material related party transactions (RPTs) with its parent, State Bank of India, and other group entities including SBI DFHI and SBI Capital Markets. All four ordinary resolutions were passed with a significant majority, exceeding 97% of the votes cast in each case. The voting, conducted via postal ballot ending March 30, 2026, also included approval for transactions with Yes Bank Limited. This ensures operational continuity and maintains the strategic business relationship within the SBI ecosystem.
முக்கிய அம்சங்கள்
Approval for Material Related Party Transactions with State Bank of India passed with 97.81% votes in favor.Transactions with SBI DFHI Limited and SBI Capital Markets Limited both received 97.84% approval from voting members.The resolution for transactions with Yes Bank Limited was approved with 97.84% of the total 369.67 million votes polled.Remote e-voting saw participation from institutional and non-institutional investors, with promoters being interested parties in the resolutions.
👀 கவனிக்க வேண்டியவை
No immediate action is required as these approvals are standard for maintaining business synergies with the parent bank. Investors should continue to monitor the volume of these transactions in annual disclosures to ensure they remain at arm's length.
Panacea Biotec has received a demand order for ₹22.88 crore from the CGST authorities, which includes a principal tax amount of ₹11.44 crore and an equivalent penalty. The dispute pertains to the alleged non-payment of GST on corporate guarantees totaling ₹864 crore issued between April 2019 and March 2022. Crucially, the company has already obtained an interim stay from the Punjab & Haryana High Court, protecting it from coercive recovery actions. The management maintains that the demand is not legally maintainable and is taking steps to contest the order.
முக்கிய அம்சங்கள்
Total demand of ₹22.88 crore comprising ₹11.44 crore GST and ₹11.44 crore penalty.Dispute relates to corporate guarantees worth ₹864 crore provided over a period of 1,074 days.Interim stay order granted by Punjab & Haryana High Court prevents coercive action by authorities.Company filed its response to the Show Cause Notice on March 27, 2026, and considers the demand non-maintainable.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final outcome of the writ petition in the High Court as it will determine if the ₹22.88 crore liability materializes. While the stay order mitigates immediate cash flow risks, the legal uncertainty remains a factor for the company's valuation.
MobiKwik Partners with Rajasthan Royals as Official Payments Partner for IPL 2026
One MobiKwik Systems Limited has entered its first-ever major sports partnership, becoming the Official Payments Partner for Rajasthan Royals for the IPL 2026 season. This strategic move is aimed at reaching the next 100 million digital payment users by leveraging the IPL's massive viewership. The partnership will promote MobiKwik's UPI, Personal Loans, and Bill Payment services through co-branded marketing and in-app integrations. As of December 2025, MobiKwik holds an 18% market share in the PPI wallet segment and serves over 186.6 million registered users.
முக்கிய அம்சங்கள்
Designated as the Official Payments Partner for Rajasthan Royals for the IPL 2026 season.Aims to leverage a user base of 186.6 million+ registered users and 4.79 million+ merchants.Company holds an 18% market share of PPI wallet Gross Transaction Value (GTV) as of Dec 2025.Partnership includes digital and in-app integrations for UPI and instant Personal Loans.Strategic focus on capturing 'young, aspirational India' to drive higher transaction volumes.
👀 கவனிக்க வேண்டியவை
Investors should watch for an uptick in user acquisition and loan disbursement volumes following the IPL season to justify the marketing spend. This move indicates an aggressive growth strategy to consolidate market share in the competitive fintech space.
IFB Industries Appoints Veteran Arup Das as Executive Director Effective March 28, 2026
IFB Industries has appointed Mr. Arup Das as an Executive Director on its Board, effective March 28, 2026. Mr. Das is a company veteran who has been with IFB since 1992 and currently serves as President of M&A and New Projects. This appointment is for an interim period until a new Chief Executive Officer or Managing Director is officially appointed. His 38 years of experience across engineering, supply chain, and marketing is expected to provide leadership stability during this transition.
முக்கிய அம்சங்கள்
Mr. Arup Das appointed as Executive Director effective March 28, 2026.The appointee has over 38 years of total experience, with 34 years dedicated to IFB Industries.Appointment serves as an interim measure until a permanent CEO or Managing Director is selected.Mr. Das previously held leadership roles in Engineering, Heat Treatment, and Supply Chain divisions.The Board meeting for this approval commenced at 11:30 a.m. and concluded at 3:00 p.m.
👀 கவனிக்க வேண்டியவை
Investors should view this as a move to ensure operational continuity using internal talent. Monitor future announcements regarding the permanent appointment of a CEO or MD for long-term strategic direction.
IFB Industries Limited has announced the resignation of Mr. Panamanna Hariharan Narayanan from his position as Managing Director (Engineering Division), effective April 1, 2026. Mr. Narayanan cited personal commitments and retirement as the primary reasons for his departure after a 2.5-year tenure with the company. The resignation was formally communicated via email on March 27, 2026, and disclosed to the exchanges on March 28, 2026. Investors should note that the transition period is significant, providing the company time to find a suitable successor.
முக்கிய அம்சங்கள்
Mr. Panamanna Hariharan Narayanan to step down as Managing Director on April 1, 2026.The resignation concludes a 2.5-year tenure leading the company's Engineering Division.Departure is attributed to personal commitments and retirement rather than operational issues.The company has approximately one year to manage the leadership transition for the division.
👀 கவனிக்க வேண்டியவை
Investors should monitor future filings for the appointment of a new Managing Director to ensure leadership continuity. No immediate action is required as the resignation is planned well in advance.
Panacea Biotec Limited has received an adverse ruling from the Commissioner of Income Tax (Appeals), New Delhi, which dismissed the company's appeals against penalty orders. These orders pertain to alleged under-reporting of income for the Assessment Years 2017-18, 2020-21, and 2021-22. The aggregate demand resulting from these penalties stands at approximately ₹9.38 crore. While the company intends to challenge this order before a higher appellate authority, the dismissal of the current appeal reinforces the immediate tax liability risk.
முக்கிய அம்சங்கள்
CIT(A) dismissed three appeals against penalty orders issued by the Assistant Commissioner of Income Tax.The total aggregate tax demand involved in the litigation is approximately ₹9.38 crore.The penalties relate to alleged under-reporting of income for AY 2017-18, 2020-21, and 2021-22.Panacea Biotec plans to file a further appeal with the next appellate authority to contest the demand.Management currently maintains that the demand will not have a relevant impact on operations or financial activities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the next appeal as a final unfavorable outcome would necessitate a ₹9.38 crore cash outflow. The news is likely to weigh slightly on the stock price in the short term due to the legal setback.
Triveni Turbine Shareholders Approve Re-appointment of Nikhil Sawhney as MD with 84.9% Majority
Triveni Turbine Limited has successfully passed a special resolution via postal ballot for the re-appointment of Mr. Nikhil Sawhney as Managing Director. The resolution received 84.91% approval from the total votes polled, ensuring leadership continuity for the company. However, the results revealed significant dissent from public institutional investors, with 40.53% of their votes cast against the proposal. Despite this institutional resistance, the resolution met the requisite majority threshold for a special resolution.
முக்கிய அம்சங்கள்
Special resolution for re-appointment of Nikhil Sawhney as MD passed with 84.91% assent.Promoter group provided full support with 100% of their 17.75 crore shares voting in favor.Public institutional investors showed notable resistance, with 40.53% (4.27 crore votes) dissenting.Total valid votes polled were 28.29 crore, representing approximately 89% of the total paid-up share capital.The resolution was deemed passed on March 26, 2026, following the conclusion of the e-voting period.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive for leadership stability, though the high institutional dissent suggests a need to monitor future governance and compensation disclosures.
BirlaNu Board Approves Increase in Corporate Guarantee Limit to Euro 55 Million
BirlaNu Limited has granted in-principle approval to enhance its corporate guarantee limit for its wholly-owned German subsidiary, BirlaNu International GmbH. The limit is being increased from Euro 45 million to Euro 55 million, an increment of Euro 10 million. This guarantee, which includes Stand-by Letters of Credit, is intended to secure existing and future loan facilities for the subsidiary and its units. The move signals continued financial backing for the company's international operations and expansion strategy.
முக்கிய அம்சங்கள்
Corporate guarantee limit enhanced from Euro 45 million to Euro 55 millionGuarantee provided for BirlaNu International GmbH, Germany, a 100% subsidiaryIncludes provisions for guarantees in the form of Stand-by Letters of Credit (SBLC)Funds will secure existing and future loan facilities for the subsidiary and its unitsBoard meeting concluded at 3:25 PM IST on March 27, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the financial health and debt-servicing capability of the German subsidiary as this increase in contingent liability ties the parent company closer to its international performance. Ensure that the additional credit headroom is being utilized for growth-oriented capital expenditure or efficient refinancing.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
